SONODRUGS
Image-controlled Ultrasound-induced Drug Delivery
| Coordinatore | PHILIPS ELECTRONICS NEDERLAND B.V.
Organization address
address: Boschdijk 525 contact info |
| Nazionalità Coordinatore | Netherlands [NL] |
| Totale costo | 15˙903˙800 € |
| EC contributo | 10˙783˙900 € |
| Programma | FP7-NMP
Specific Programme "Cooperation": Nanosciences, Nanotechnologies, Materials and new Production Technologies |
| Code Call | FP7-NMP-2007-LARGE-1 |
| Funding Scheme | CP-IP |
| Anno di inizio | 2008 |
| Periodo (anno-mese-giorno) | 2008-11-01 - 2012-10-31 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
PHILIPS ELECTRONICS NEDERLAND B.V.
Organization address
address: Boschdijk 525 contact info |
NL (EINDHOVEN) | coordinator | 0.00 |
| 2 |
"THE SCHOOL OF PHARMACY, UNIVERSITY OF LONDON"
Organization address
address: Brunswick Square 29-39 contact info |
UK (LONDON) | participant | 0.00 |
| 3 |
AALTO-KORKEAKOULUSAATIO
Organization address
address: OTAKAARI 1 contact info |
FI (ESPOO) | participant | 0.00 |
| 4 |
ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM
Organization address
address: 's Gravendijkwal 230 contact info |
NL (ROTTERDAM) | participant | 0.00 |
| 5 |
HELSINGIN YLIOPISTO
Organization address
address: YLIOPISTONKATU 4 contact info |
FI (HELSINGIN YLIOPISTO) | participant | 0.00 |
| 6 |
LIPOID GMBH
Organization address
address: FRIGENSTRASSE 4 contact info |
DE (LUDWIGSHAFEN) | participant | 0.00 |
| 7 |
NANOBIOTIX SA
Organization address
address: "RUE DE WATTIGNIES, BATIMENT B 60" contact info |
FR (PARIS) | participant | 0.00 |
| 8 |
PHILIPS OY
Organization address
address: AYRITIE 4 contact info |
FI (VANTAA) | participant | 0.00 |
| 9 |
PHILIPS TECHNOLOGIE GMBH
Organization address
address: LUEBECKERTORDAM 5 contact info |
DE (HAMBURG) | participant | 0.00 |
| 10 |
TECHNISCHE UNIVERSITEIT EINDHOVEN
Organization address
address: DEN DOLECH 2 contact info |
NL (EINDHOVEN) | participant | 0.00 |
| 11 |
UNIVERSITA DEGLI STUDI DI UDINE
Organization address
address: VIA PALLADIO 8 contact info |
IT (UDINE) | participant | 0.00 |
| 12 |
UNIVERSITAIR MEDISCH CENTRUM UTRECHT
Organization address
address: HEIDELBERGLAAN 100 contact info |
NL (UTRECHT) | participant | 0.00 |
| 13 |
UNIVERSITE FRANCOIS RABELAIS DE TOURS
Organization address
address: RUE DU PLAT D ETAIN 60 contact info |
FR (TOURS) | participant | 0.00 |
| 14 |
UNIVERSITE VICTOR SEGALEN BORDEAUX II
Organization address
address: RUE LEO SAIGNAT 146 contact info |
FR (BORDEAUX CEDEX) | participant | 0.00 |
| 15 |
UNIVERSITEIT GENT
Organization address
address: SINT PIETERSNIEUWSTRAAT 25 contact info |
BE (GENT) | participant | 0.00 |
| 16 |
UNIVERSITY COLLEGE LONDON
Organization address
address: GOWER STREET contact info |
UK (LONDON) | participant | 0.00 |
| 17 |
UNIVERSITY OF CYPRUS
Organization address
address: KALLIPOLEOS STREET 75 contact info |
CY (NICOSIA) | participant | 0.00 |
| 18 |
WESTFAELISCHE WILHELMS-UNIVERSITAET MUENSTER
Organization address
address: SCHLOSSPLATZ 2 contact info |
DE (MUENSTER) | participant | 0.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'The demographic changes in Europe towards an aging society will coincide with increasing morbidity of the population. European citizens need improved access to state-of-the-art medical care especially in oncology and cardiology, while keeping expenditures on healthcare affordable. New therapeutic options such as externally triggered local drug release at the diseased area hold promise to solve urgent medical needs: improved treatment with reduced side effects, fewer burdens to the patient and faster recovery after intervention. Nanomedicine, the application of nanomaterials and nanotechnology to healthcare, will enable breakthroughs in clinical practice. SONODRUGS addresses clinical needs by developing novel drug delivery technologies for localised treatment of cardiovascular disease and cancer. SONODRUGS develops drug delivery concepts where drug release can be triggered by focused ultrasound induced pressure or temperature stimuli within the diseased tissue. New drug loaded nanocarriers will be designed for tailored drug delivery systems that respond to either of the two stimuli. Medical imaging, i.e. magnetic resonance imaging and ultrasound imaging, will be used to guide, follow and quantify the drug delivery process. Therapy efficacy using different drug delivery systems will be assessed in vitro and subsequently in preclinical studies. Starting form research on a broad range of materials and drugs, two nanocarriers will be finally selected, optimized and produced on a pilot scale in combination with image-guided delivery tools and methods. SONODRUGS binds expertise in materials research (Philips, TUE, GhentRGN, HBBG); material production (Nanobiotix, Lipoid); clinical knowledge in oncology (UTours, HBBG) and cardiology (UKB); in vitro and preclinical validation (UTours, ErasmusMC, UKB); research on imaging techniques (UCY, Philips, IMF); pharmacokinetics, toxicology and biodistribution (ULSOP, IPT).'